is retatrutide on the market ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide: The New Triple-Agonist Weight
Description
Indications and Efficacy: Obesity Treatment: In the Phase II clinical trial, patients in the highest dose group (12 mg) lost an average of 24.2% weight after 48 weeks, and some patients lost more than 30%
Telemedicine With GLP-1 Behavior Program Shows Significant Declines in Weight, Blood Pressure | ADA 2025
Please update your browser for more security and a better experience
Who is not a good candidate for GLP-1
Shelf life of lyophilized tirzepatide Shelf life varies dramatically depending on the form and storage conditions
We are not prescribing it
